SPRO logo

SPERO THERAPEUTICS INC

SPRONASDAQ
πŸ† #4246 by market capUS Equity
$0.74β–Ό $0.09 (βˆ’11.03%)
Market closed Β· at close
πŸ””
Track SPRO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 11.0%
7dβ–Ό 25.5%
14dβ–Ό 28.6%
30dβ–Ό 33.4%
ytdβ–Ό 68.3%
1yβ–Ό 68.1%
🏦Market Cap
$43M
Small Cap
πŸ“ˆRevenue Growth (YoY)
24.3%
Healthy
πŸ“ŠGross Margin
100.0%
High
πŸ’΅FCF Margin
-101.3%
Thin
βš–οΈP/S Ratio
1.1x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.73 – $0.80
52-Week Range
$0.73 – $3.08
Volume (shares)
26,369
Avg Volume (shares)
β€”
Shares Outstanding
58.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$60M
Last Q Revenue
β€”
P/E Ratio
-1.5
P/S Ratio
1.1x
EPS (TTM)
$-0.51
Dividend Yield
0.00%
Dilution (1yr)
+9.9%
SPRO logo

SPERO THERAPEUTICS INC

SPRO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$60Mβ–² +24.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–Ό βˆ’198.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$24Kβ–Ό βˆ’100.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–Ό βˆ’46.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.4Mβ–² +9.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37Mβ–Ό βˆ’$11M YoY
StockOtter Β· stockotter.space

About SPERO THERAPEUTICS INC

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.